SCHEMBL578005

SCHEMBL578005

Cc1cccc(C)c1C(C)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.46
CA2 P00918 3/20 0.46
CA7 P43166 2/20 0.46
CA9 Q16790 2/20 0.46
ALDH1A1 P00352 2/20 0.46
CYP1A2 P05177 3/20 0.41
CYP2A6 P11509 2/20 0.41
TSHR P16473 4/20 0.40
TRPA1 O75762 2/20 0.40
ACHE P22303 1/20 0.40
ATM Q13315 1/20 0.40
SCN4A P35499 4/20 0.35
LMNA P02545 3/20 0.35
MAOA P21397 2/20 0.35
CYP3A4 P08684 2/20 0.35
HTR2B P41595 2/20 0.35
SCN1A P35498 2/20 0.35
SCN5A Q14524 2/20 0.35
SCN9A Q15858 2/20 0.35
MAOB P27338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29558466 0.85 TRPA1 (0.50) CA1CA2CA7CA9ALDH1A1
SCHEMBL19979060 0.84 ALDH1A1 (0.37) CA1CA2CA7CA9ALDH1A1
SCHEMBL22728357 0.84 ACHE (0.46) CA1CA2CA7CA9ALDH1A1
SCHEMBL8973695 0.84 CD44 (0.48) CA1CA2CA7CA9ALDH1A1
SCHEMBL6745083 0.84 ALDH1A1 (0.46) CA1CA2CA7CA9ALDH1A1
SCHEMBL24481223 0.80 GABRA1 (0.45) ALDH1A1TSHRSCN4ALMNACYP3A4
SCHEMBL8932197 0.80 ALDH1A1 (0.48) CA1CA2CA7CA9ALDH1A1
SCHEMBL12238610 0.79 CA1 (0.42) CA1CA2CA7CA9ALDH1A1
SCHEMBL23364851 0.79 IRAK4 (0.41) CA1CA2CA7CA9ALDH1A1
SCHEMBL29932941 0.79 IRAK4 (0.41) CA1CA2CA7CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111141849-B Liquid phase detection separation method for positional isomer of dexmedetomidine initial raw material 江苏开元药业有限公司 2023-11-03 CN claimed
CN-113325096-B Detection method of 1- (2,3-dimethylphenyl) ethanol related substances 石家庄四药有限公司 2022-12-13 CN claimed
CN-113325096-A Detection method of 1- (2, 3-dimethylphenyl) ethanol related substances 石家庄四药有限公司 2021-08-31 CN claimed
CN-111141849-A Liquid phase detection and separation method for positional isomer of dexmedetomidine starting material 江苏开元药业有限公司 2020-05-12 CN claimed
US-20260000642-A1 PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS TAY THERAPEUTICS LTD (GB) 2026-01-01 US disclosed
US-20250263370-A1 PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS Tay Therapeutics Limited (GB) 2025-08-21 US disclosed
EP-4558224-A1 PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS Tay Therapeutics Limited (GB) 2025-05-28 EP disclosed
CN-118978425-A Process for preparing substituted 2-aryl ethanol 拜耳作物科学股份公司 2024-11-19 CN disclosed
CN-108473402-B Process for preparing substituted 2-aryl ethanol 拜耳作物科学股份公司 2024-07-19 CN disclosed
WO-2024018423-A1 PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS Tay Therapeutics Limited (GB) 2024-01-25 WO disclosed
CN-111141849-B Liquid phase detection separation method for positional isomer of dexmedetomidine initial raw material 江苏开元药业有限公司 2023-11-03 CN disclosed
CN-113325096-B Detection method of 1- (2,3-dimethylphenyl) ethanol related substances 石家庄四药有限公司 2022-12-13 CN disclosed
US-20030064991-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. 2003-04-03 US disclosed
WO-2002072549-A1 FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-09-19 WO disclosed
CN-1344270-A Functionalized heterocycles as chemokine receptor modulators THOUSAND YEARS MEDICAMENTS INC (US) 2002-04-10 CN disclosed
EP-1144415-A2 FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS WARNER-LAMBERT COMPANY (US) 2001-10-17 EP disclosed
WO-2000042045-A2 FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS WARNER-LAMBERT COMPANY (US) 2000-07-20 WO disclosed
US-4742073-A ANTIGLAUCOMA BUNDGAARD HANS (DK) 1988-05-03 US disclosed
EP-0149976-A2 Substituted imidazoles CIBA-GEIGY AG (CH) 1985-07-31 EP disclosed
EP-0106541-A2 Pilocarpine prodrugs Bundgaard, Hans (DK) 1984-04-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064991-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor ACKR3, CCR5, CXCR4 CA1 3029/4885CA2 3312/4885CA7 2839/4885
US-20260000642-A1 PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS BET1, BRD4, PHKB CA1 4153/4885CA2 915/4885CA7 3370/4885
US-20250263370-A1 PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS BET1, PHKB, BRD4 CA1 4585/4885CA2 3704/4885CA7 4629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.